Background: Viral genesis is the most common cause of myocarditis. COVID-19-associated myocarditis seems to be a notable extrapulmonary manifestation, which may result in the need for a different treatment. There has been no positive polymerase chain reaction (PCR) testing of SARS-CoV-2 in heart specimens, thus far. Case summary: A 48-year-old male patient presented with fever, dyspnoea, and haemoptysis. Laboratory findings showed highly elevated inflammatory and cardiac damage markers. Thoracic computed tomography (CT) revealed bilateral, patchy peripheral ground-glass opacities with a crazy-paving pattern, focal consolidations, and mild pleural effusions. Cardiac imaging with echocardiography and magnetic resonance imaging (MRI) detected a reduced biventricular function. MRI additionally showed myocardial oedema and late gadolinium enhancement. Lung and heart biopsies were performed, revealing alveolitis with necrosis and acute lymphocytic myocarditis. Testing for usual cardiotropic viruses was negative, and no aspects of vasculitis or granuloma could be found. Due to fulfilling the criteria, the patient was diagnosed with rheumatic vasculitis. Treatment with cyclophosphamide and steroids was initiated. Later, the patient reported a history of travel to Tyrol in mid January. Consequently, PCR testing for SARS-CoV-2 was performed, which was positive in the heart specimen. Immunosuppressive treatment was discontinued. During a follow-up visit at the end of April, the patient’s recovery was stable. Discussion: In COVID-19 infections, myocardial inflammation can be present as an extrapulmonary manifestation. Positive PCR testing confirms myocardial invasion of the virus. Imaging and laboratory studies correlate with the histopathological findings, and thus should be performed in COVID-19 patients who are suspicious for myocarditis. Supportive treatment with steroids may be useful in these patients.
1 January 2020 in International Journal of Hyperthermia
Aim of this randomized controlled trial was to evaluate the effects of serial locally applied water-filtered infrared A radiation (sl-wIRAR) in patients with axial spondyloarthritis (axSpA). axSpA ...
Objectives: Multimodal rheumatologic complex therapy (MRCT) delivers various modalities of physical therapy (PT) to patients with rheumatic diseases. We conducted a monocentric retrospective analysis of the effects of MRCT on pain and disease activity in patients with primary (PFM) and secondary fibromyalgia (SFM). Methods: 102 treatment episodes (N) applied to 83 patients (n) with PFM (N = 50;n = 39) and SFM (N = 52,n = 44) were analysed. Of the latter, 23 had rheumatoid arthritis (RA) and 21 spondyloarthritis (SpA). We evaluated changes in pain intensity, functional status and disease activity before and after a MRCT episode. In addition, we assessed influences of various patient characteristics and analysed treatment responses in PFM and SFM. Results: MRCT resulted in significant reduction of pain (NRS,p < 0.0001) and disease activity (FIQ,p = 0.001). In SFM, disease activity of the underlying disease (i.e. RA or SpA) was significantly reduced. Various aspects of the disease did not have a significant effect on the outcome parameters. Treatment effects were not significantly different in PFM and SFM. Conclusion: MRCT significantly decreases pain and disease activity in patients with FM, irrespective of the course of disease, and is equally effective in both PFM and SFM, thus underlining the importance of PT in the treatment of FM.